Prostate-derived Ets factor, an oncogenic driver in breast cancer.
Published
Journal Article (Review)
Prostate-derived Ets factor (PDEF), a member of the Ets family of transcription factors, differs from other family members in its restricted expression in normal tissues and its unique DNA-binding motif. These interesting attributes coupled with its aberrant expression in cancer have rendered PDEF a focus of increasing interest by tumor biologists. This review provides a current understanding of the characteristics of PDEF expression and its role in breast cancer. The bulk of the evidence is consistent with PDEF overexpression in most breast tumors and an oncogenic role for this transcription factor in breast cancer. In addition, high PDEF expression in estrogen receptor-positive breast tumors showed significant correlation with poor overall survival in several independent cohorts of breast cancer patients. Together, these findings demonstrate PDEF to be an oncogenic driver of breast cancer and a biomarker of poor prognosis in this cancer. Based on this understanding and the limited expression of PDEF in normal human tissues, the development of PDEF-based therapeutics for prevention and treatment of breast cancer is also discussed.
Full Text
Duke Authors
Cited Authors
- Sood, AK; Geradts, J; Young, J
Published Date
- May 2017
Published In
- Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Volume / Issue
- 39 / 5
Start / End Page
- 1010428317691688 -
PubMed ID
- 28468594
Pubmed Central ID
- 28468594
Electronic International Standard Serial Number (EISSN)
- 1423-0380
Digital Object Identifier (DOI)
- 10.1177/1010428317691688
Language
- eng
Conference Location
- United States